Trials / Completed
CompletedNCT01022970
Efficacy and Safety of QAX576 in Patients With Eosinophilic Esophagitis
A Double Blinded Randomized Placebo-controlled Trial of Intravenous QAX576 in the Treatment of Eosinophilic Esophagitis (EoE)
- Status
- Completed
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 25 (actual)
- Sponsor
- Novartis Pharmaceuticals · Industry
- Sex
- All
- Age
- 18 Years – 50 Years
- Healthy volunteers
- Not accepted
Summary
This study is designed to investigate the effects of a 12 week course of intravenous QAX576 6mg/kg every 4 weeks in reducing the number of eosinophils in the esophagus of EoE patients by 75% or greater when compared with baseline.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | QAX576 placebo | |
| DRUG | QAX576 |
Timeline
- Start date
- 2009-11-01
- Primary completion
- 2012-02-01
- First posted
- 2009-12-01
- Last updated
- 2021-03-11
Locations
5 sites across 1 country: United States
Source: ClinicalTrials.gov record NCT01022970. Inclusion in this directory is not an endorsement.